Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis. sufferers with intermediate- or high-risk MF, including primary MF (PMF), post-polycythemia vera MF (PPV-MF), and post-essential thrombocythemia MF (PET-MF), as well as sufferers with PV who’ve had an insufficient response to or are intolerant of hydroxyurea… Continue reading Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the